Molina Healthcare's stock experienced a sharp 7.25% decline in post-market trading on Wednesday, following the release of its second-quarter 2026 financial results.

While the company's adjusted earnings per share of $1.51 beat the consensus estimate of $1.39, investors focused on a severe 74% year-over-year drop in GAAP earnings per share to $1.19. Revenue also declined 4.8% to $10.87 billion, reflecting lower membership.

The selloff was primarily driven by concerning elements within the company's updated full-year guidance. Molina disclosed that its traditional Medicare Advantage Prescription Drug (MAPD) products are underperforming, projecting a $1.00 per share earnings drag. Furthermore, the implementation of a new Florida Medicaid contract in the fourth quarter is expected to contribute an additional loss of $1.50 per share. Analysts noted that the modest increase in the company's annual profit forecast to at least $5.25 per share was overshadowed by these specific headwinds and ongoing pressure in its Obamacare Marketplace business, where a larger share of enrollees required costly medical care than anticipated.